BACKGROUND: In human basophils from different subjects, maximum IgE-mediated histamine release and the level of Syk protein expression correlate well. Recent studies suggest that in some patients treated with omalizumab, the response to stimulation with anti-IgE antibody increases. In unrelated studies there is also evidence that the composition of FcepsilonRI in basophils differs among subjects. This observation raised the possibility that the stoichiometry of FcRbeta/FcepsilonRIalpha is not fixed to a 1:1 ratio and might be modifiable during changes in the basophil's environment. OBJECTIVE: We sought to determine whether treatment with omalizumab results in increases in Syk expression and anti-IgE-mediated histamine release and disproportionately alters the relative presence of FcRbeta and FcepsilonRIalpha. METHOD: Syk, FcepsilonRIalpha, and FcRbeta expression was monitored during the treatment of subjects with omalizumab. RESULTS: Treatment with omalizumab reduced histamine release from peripheral blood leukocytes stimulated with cat allergen in vitro, but histamine release stimulated with anti-IgE antibody increased 2-fold. Expression of Syk increased 1.86-fold. There was no change in the expression of c-Cbl, a signaling element that is sensitive to the presence of IL-3, and no increase in response to formyl-met-leu-phe (tripeptide), a response that also increases in the presence of IL-3. There was a 60% decrease in the FcRbeta/FcepsilonRIalpha ratio in patients treated with omalizumab. CONCLUSIONS: In the context of previous studies, these studies provide support for a proposal that Syk expression is modulated in vivo through an IgE-dependent mechanism and that the ratio of FcepsilonRI alpha and beta subunits in basophils is influenced by factors extrinsic to the cell. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND: In human basophils from different subjects, maximum IgE-mediated histamine release and the level of Syk protein expression correlate well. Recent studies suggest that in some patients treated with omalizumab, the response to stimulation with anti-IgE antibody increases. In unrelated studies there is also evidence that the composition of FcepsilonRI in basophils differs among subjects. This observation raised the possibility that the stoichiometry of FcRbeta/FcepsilonRIalpha is not fixed to a 1:1 ratio and might be modifiable during changes in the basophil's environment. OBJECTIVE: We sought to determine whether treatment with omalizumab results in increases in Syk expression and anti-IgE-mediated histamine release and disproportionately alters the relative presence of FcRbeta and FcepsilonRIalpha. METHOD:Syk, FcepsilonRIalpha, and FcRbeta expression was monitored during the treatment of subjects with omalizumab. RESULTS: Treatment with omalizumab reduced histamine release from peripheral blood leukocytes stimulated with cat allergen in vitro, but histamine release stimulated with anti-IgE antibody increased 2-fold. Expression of Syk increased 1.86-fold. There was no change in the expression of c-Cbl, a signaling element that is sensitive to the presence of IL-3, and no increase in response to formyl-met-leu-phe (tripeptide), a response that also increases in the presence of IL-3. There was a 60% decrease in the FcRbeta/FcepsilonRIalpha ratio in patients treated with omalizumab. CONCLUSIONS: In the context of previous studies, these studies provide support for a proposal that Syk expression is modulated in vivo through an IgE-dependent mechanism and that the ratio of FcepsilonRI alpha and beta subunits in basophils is influenced by factors extrinsic to the cell. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Authors: Calman Prussin; Daniel T Griffith; Kevin M Boesel; Henry Lin; Barbara Foster; Thomas B Casale Journal: J Allergy Clin Immunol Date: 2003-12 Impact factor: 10.793
Authors: R P Schleimer; C P Derse; B Friedman; S Gillis; M Plaut; L M Lichtenstein; D W MacGlashan Journal: J Immunol Date: 1989-08-15 Impact factor: 5.422
Authors: Janet M Oliver; Christy A Tarleton; Laura Gilmartin; Tereassa Archibeque; Clifford R Qualls; Lorena Diehl; Bridget S Wilson; Mark Schuyler Journal: Int Arch Allergy Immunol Date: 2009-10-22 Impact factor: 2.749
Authors: Henry Lin; Kevin M Boesel; Daniel T Griffith; Calman Prussin; Barbara Foster; F A Romero; Robert Townley; Thomas B Casale Journal: J Allergy Clin Immunol Date: 2004-02 Impact factor: 10.793
Authors: Ratko Djukanović; Susan J Wilson; Monica Kraft; Nizar N Jarjour; Mark Steel; K Fan Chung; Weibin Bao; Angel Fowler-Taylor; John Matthews; William W Busse; Stephen T Holgate; John V Fahy Journal: Am J Respir Crit Care Med Date: 2004-06-01 Impact factor: 21.405